Clinical Trial Update: REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer [Phase 1, Phase 2]

View source ↗

Summary

This entry covers the REACTION trial (NCT03610711) evaluating nivolumab, alone or with other immune checkpoint inhibitors, after targeted systemic radiation in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagogastric Cancer
• Gastroesophageal Cancer

Drugs mentioned

• nivolumab (Opdivo) (nivolumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Gastroesophageal Cancer, Immune Checkpoint Inhibition | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING